Norethisterone transdermal - Allergan

Drug Profile

Norethisterone transdermal - Allergan

Alternative Names: NEA TDS; Norethindrone acetate patch; Norethindrone transdermal - Allergan; Progestin-only patch

Latest Information Update: 16 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Watson Pharmaceuticals
  • Developer Allergan
  • Class Hormonal replacements; Norpregnenes; Oral contraceptives; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Pregnancy

Most Recent Events

  • 16 Feb 2016 No development reported - Preregistration for Pregnancy (Prevention) in USA (Transdermal)
  • 24 Dec 2013 Actavis receives complete response letter from the FDA for norethisterone transdermal in Contraception
  • 13 May 2013 PDUFA action date of 27/12/2013 assigned by US FDA for norethisterone transdermal for Contraception
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top